A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT07284758
Trial Phases:	Phase II	Protocol IDs:	CFT7455-2101 (primary) NCI-2026-01765
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	C4 Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT07284758

Summary

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma
activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in
combination with dexamethasone in participants with relapsed/refractory multiple myeloma
(r/r MM).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.